Extension of microRNA expression pattern associated with high-risk neuroblastoma
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Infant MeSH
- Humans MeSH
- MicroRNAs genetics metabolism MeSH
- Biomarkers, Tumor genetics MeSH
- Neuroblastoma genetics MeSH
- Prognosis MeSH
- Gene Expression Regulation, Neoplastic MeSH
- Gene Expression Profiling MeSH
- Check Tag
- Infant MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- MicroRNAs MeSH
- Biomarkers, Tumor MeSH
Clinical behavior of neuroblastoma (NBL) is remarkably heterogeneous, as it ranges from spontaneous regression to aggressive clinical phenotype and death. There is increasing body of evidence demonstrating that microRNAs could be considered the potential biomarkers for clinical applications in NBL. In this report, we focus on molecular characterization of high-risk as well as low-risk and intermediate-risk NBL cases in the context of the microRNA expression profile that is specific for the given risk category of the disease. We investigated a total of 30 NBL patients, out of whom there were 19 patients with low- to intermediate-risk and 11 with high-risk NBLs as defined by the Clinical Oncology Group. We determined the expression profiles of 754 microRNAs (miRNAs), whereas the miRNA expression levels were normalized to RNU44, mean expression levels were calculated, and data were analyzed by use of the microarray biostatistical approaches. We identified the signature of 38 miRNAs differentially expressed between these groups of NBL patients (P < 0.05): 17 miRNAs were upregulated and 21 miRNAs were downregulated in the tumors of high-risk NBL patients. We confirm some of the previous observations and we report several new microRNAs associated with aggressive NBL, both being relevant subjects for further translational validation and functional studies.
See more in PubMed
Cancer Res. 2007 Feb 1;67(3):976-83 PubMed
Cancer Biol Ther. 2010 Mar 15;9(6):446-52 PubMed
Int J Cancer. 2012 Jun 1;130(11):2591-8 PubMed
Mol Pharmacol. 2010 Jan;77(1):102-9 PubMed
Br J Cancer. 2011 Oct 25;105(9):1352-61 PubMed
Semin Cancer Biol. 2011 Oct;21(4):238-44 PubMed
Cancer Res. 2010 Oct 15;70(20):7841-50 PubMed
Clin Cancer Res. 2010 Jun 1;16(11):2971-8 PubMed
Nucleic Acids Res. 2010 Sep;38(17):5919-28 PubMed
Nat Rev Cancer. 2003 Mar;3(3):203-16 PubMed
Pediatr Clin North Am. 2008 Feb;55(1):97-120, x PubMed
BMC Genomics. 2010 Dec 02;11 Suppl 4:S5 PubMed
PLoS One. 2009 Nov 16;4(11):e7850 PubMed
Clin Cancer Res. 2011 Dec 15;17(24):7684-92 PubMed
EMBO Mol Med. 2012 Mar;4(3):143-59 PubMed
Mol Cell Biol. 2004 Apr;24(7):2662-72 PubMed
Br J Cancer. 2012 Sep 4;107(6):967-76 PubMed
Nat Rev Genet. 2009 Oct;10(10):704-14 PubMed
Int J Cancer. 2010 Nov 15;127(10):2374-85 PubMed
BMC Cancer. 2011 Jan 25;11:33 PubMed
